Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.68 USD | -0.43% | -2.45% | +67.74% |
05-01 | Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154 | CI |
04-12 | Lipocine Says LPCN 2401 Shows Improved Body Composition in Mid-Stage Trial | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+67.74% | 25.03M | |
+8.96% | 105B | |
-1.43% | 104B | |
+4.40% | 22.94B | |
-12.15% | 22.34B | |
-4.36% | 19.25B | |
-39.98% | 17.08B | |
-10.04% | 16.96B | |
+38.61% | 12.63B | |
+313.59% | 8.49B |
- Stock Market
- Equities
- LPCN Stock
- News Lipocine Inc.
- Lipocine : to Settle Intellectual Property Lawsuit With Clarus Therapeutics